© 2024 Cogora - All Rights Reserved

'); slot2 = googletag.defineSlot('/21804779673/hpe_live/mpu1', [[300, 600], [300, 250], [300, 1000]], 'div-gpt-ad-1560526566997-0').setTargeting('test', 'event').setTargeting(REFRESH_KEY, REFRESH_VALUE).addService(googletag.pubads()); slot3 = googletag.defineSlot('/21804779673/hpe_live/mpu2', [300,250], 'div-gpt-ad-1560784220575-0').setTargeting('test', 'event').setTargeting(REFRESH_KEY, REFRESH_VALUE).addService(googletag.pubads()); slot4 = googletag.defineSlot('/21804779673/hpe_live/mpu3', [300,250], 'div-gpt-ad-1560784251022-0').setTargeting('test', 'event').setTargeting(REFRESH_KEY, REFRESH_VALUE).addService(googletag.pubads()); slot5 = googletag.defineSlot('/21804779673/hpe_live/mpu4', [300, 250], 'div-gpt-ad-1563274753432-0').setTargeting('test', 'event').setTargeting(REFRESH_KEY, REFRESH_VALUE).addService(googletag.pubads()); googletag.defineSlot('/21804779673/hpe_live/slider', [1, 1], 'div-gpt-slider').addService(googletag.pubads()); googletag.defineSlot('/21804779673/hpe_live/skinleft', [146, 900], 'div-gpt-ad-1679485212314-0').addService(googletag.pubads()); googletag.defineSlot('/21804779673/hpe_live/skinright', [146, 900], 'div-gpt-ad-1679485314324-0').addService(googletag.pubads()); slot1 = googletag.defineSlot('/21804779673/hpe_live/leaderboard', [[970, 250], [728, 90]], 'div-gpt-ad-1579859448100-0').setTargeting('test', 'event').setTargeting(REFRESH_KEY, REFRESH_VALUE).addService(googletag.pubads()); googletag.defineSlot('/21804779673/hpe_live/footer', [728, 90], 'div-gpt-ad-1563274691467-0').addService(googletag.pubads()); googletag.defineSlot('/21804779673/hpe_live/Overlay', [640, 480], 'div-gpt-ad-1642681358066-0').addService(googletag.pubads()); googletag.defineSlot('/21804779673/hpe_live/stickyfoot', [ [970, 250], [728, 90] ], 'dfp_stickyfooter').addService(googletag.pubads()); var targeturl="diabetes"; console.log("DFP set url-hpe='"+targeturl+"'"); googletag.pubads().collapseEmptyDivs(); googletag.pubads().enableSingleRequest(); // googletag.pubads().disableInitialLoad(); // BDG 03.03.2021 googletag.pubads().enableLazyLoad({ fetchMarginPercent: 0, // When the slot enters the viewport. renderMarginPercent: 0, }); // START OF Google Ads Manager Code which is refreshing the ad once it is viewable // googletag.pubads().addEventListener('impressionViewable', function(event) { var slot = event.slot; if (slot.getTargeting(REFRESH_KEY).indexOf(REFRESH_VALUE) > -1) { setTimeout(function() { googletag.pubads().refresh([slot]); }, SECONDS_TO_WAIT_AFTER_VIEWABILITY * 1); } }); // END OF Google Ads Manager Code which is refreshing the ad once it is viewable // googletag.enableServices(); }); //--> jQuery(window).scroll(function() { checkStick(); }); var mbannerid = '#div-gpt-ad-1563273235586-0'; var mfooterid = '#footermobilebanner'; var dfooterid = '#div-gpt-ad-1563274691467-0'; // Desktop sticky check function checkStick() { var launched = false; if (jQuery(window).height() > 500) { if (!jQuery('#dfp_stickyfooter').hasClass("closed")) { if (jQuery('#dfp_stickyfooter > div').length) { if (!jQuery('#dfp_stickyfooter > div').hasClass("cog-mb-sticky")) { var width = jQuery('#dfp_stickyfooter > div > iframe').width(); var height = jQuery('#dfp_stickyfooter > div > iframe').height(); if (parseInt(width) > 0) { launched = true; jQuery('#dfp_stickyfooter').attr('style', 'height: '+(height+30)+'px;').addClass('opened'); jQuery('#dfp_stickyfooter').append(''); jQuery('#dfp_stickyfooter > div').addClass('cog-mb-sticky floating footer'); jQuery('#dfp_stickyfooter > div').attr('style', 'position:absolute; bottom:0;'); jQuery('#dfp_stickyfooter svg.close').on('click', function() { jQuery(this).parent().removeClass('opened').addClass('closed'); }); } } } } } if (!launched) { // Ad not ready yet window.setTimeout(checkStick, 250); } } jQuery(document).ready(function() {checkStick();});

This site is intended for health professionals only

Home > News > Diabetes > Diabetes T-cell treatment advance

Published on 26 August 2008

Share this story:

RELATED ARTICLES

Diabetes T-cell treatment advance

teaser

A way to isolate and kill defective immune system T-cells that cause insulin-dependent diabetes is being researched by scientists using tumour necrosis factor (TNF).

Researchers at Massachusetts General Hospital in Boston have found that such treatment leads to the death of these wayward T-cells while leaving other parts of the immune system unharmed.

The new research involved T-cells from 1,000 patients with type 1 diabetes, other autoimmune disorders, and healthy volunteers.

Scientists found that a synthetic chemical similar to TNF caused “killer” T-cells in diabetics and patients with other autoimmune conditions to self-destruct, while T-cells from healthy participants were left unharmed.

Further experiments with blood samples from several diabetic patients confirmed that only “killer” T-cells, that threatened the pancreas were targeted by the treatment. Others programmed to attack two common viruses were not affected.

In a previous study, diabetic mice given the treatment regenerated healthy islet cells and produced normal levels of insulin. Effectively, the mice were cured.

Dr Denise Faustman said: “Our studies showed that we could selectively kill the defective autoimmune cells. These results show that the same selective destruction can occur in human cells and connect our animal studies with the protocol in our clinical trial”.

Copyright PA Business 2008

Dr Denise Faustman

Most read

1

Transcranial magnetic stimulation brain connectivity changes in major depression visible on MRI scan

2

Oral vitamin A could become an alternative to isotretinoin for acne

3

Amino acids supplement reduces muscle wasting and improves gut function in critically ill

4

Less than two-thirds of patients alive 10 years after out-of-hospital cardiac arrest

5

Launch of the new Hospital Pharmacy Europe Mobile App

Be in the know

Subscribe to Hospital Pharmacy Europe newsletter and magazine

Share this story:

RELATED ARTICLES

x